Holen Sie sich die Stockscreener-App
124.12
0.83%
1.02
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences (NBIX) Is Down 12.1% After Issuing 2026 INGREZZA Sales GuidanceWhat's Changed - simplywall.st
A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance - Yahoo Finance
How cyclical is Neurocrine Biosciences Inc.’s revenue streamWeekly Investment Recap & Low Risk Profit Maximizing Plans - mfd.ru
NBIX Rating Maintained, Price Target Lowered by Wells Fargo | NB - GuruFocus
Wells Fargo & Company Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Krilogy Financial LLC Makes New $1.27 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment - ChartMill
Neurocrine Biosciences Enters New Growth Phase With Broader Revenue Mix - simplywall.st
Neurocrine Biosciences: Growth Beyond Just Ingrezza (NASDAQ:NBIX) - Seeking Alpha
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - BioPharma Dive
Neurocrine Biosciences (NASDAQ:NBIX) Given New $204.00 Price Target at Citigroup - MarketBeat
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance - Benzinga
Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting (NASDAQ:NBIX) - Seeking Alpha
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at Royal Bank Of Canada - MarketBeat
BMO Capital Markets Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says - marketscreener.com
Wedbush Adjusts Neurocrine Biosciences Price Target to $151 From $149, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $151.00 at Wedbush - MarketBeat
Neurocrine Bio. stock price target lowered to $192 at H.C. Wainwright - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 9.3% Following Analyst Downgrade - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Given New $192.00 Price Target at HC Wainwright - MarketBeat
Needham & Company LLC Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $185.00 - MarketBeat
RBC Trims Price Target on Neurocrine Biosciences to $177 From $180, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript - Insider Monkey
Forecasting The Future: 10 Analyst Projections For Neurocrine Biosciences - Benzinga
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Impax Asset Management Group plc - MarketBeat
Is Neurocrine Biosciences (NBIX) Pricing Reflecting Its Strong 1 Year Share Performance? - simplywall.st
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN
Neurocrine Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Neurocrine Biosciences (NASDAQ:NBIX) Posts Earnings Results, Misses Estimates By $0.48 EPS - MarketBeat
Neurocrine Biosciences Q4 Earnings Call Highlights - MarketBeat
Neurocrine Q4 2025 slides: INGREZZA, CRENESSITY fuel 22% annual growth - Investing.com India
Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises By Investing.com - Investing.com India
Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises - Investing.com
Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates - Yahoo Finance
Neurocrine: Q4 Earnings Snapshot - KVUE
Neurocrine: Fourth Quarter Earnings Overview - Bitget
Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance By Investing.com - Investing.com Australia
Neurocrine Biosciences Fiscal Q4 Adjusted Earnings, Revenue Rise; Sets INGREZZA FY Guidance - marketscreener.com
Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance - Investing.com
Neurocrine Biosciences Inc Profit Advances In Q4 - Nasdaq
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M - marketscreener.com
Neurocrine Biosciences (NASDAQ: NBIX) posts 2025 INGREZZA surge and details DOJ probe - Stock Titan
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 - PR Newswire
Neurocrine Biosciences Q4 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
Neurocrine earnings in focus as Crenessity launch, Ingrezza rivalry heat up - Investing.com Canada
What are Neurocrine Biosciences Inc.’s growth leversStop Loss & Reliable Volume Spike Alerts - mfd.ru
Wesbanco Bank Inc. Makes New $1.26 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Preview: Neurocrine Biosciences's Earnings - Benzinga
Neurocrine Biosciences (NASDAQ:NBIX) Shareholders Have Earned a 11% CAGR Over the Last Three Years - 富途牛牛
Candriam S.C.A. Sells 10,906 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Azzad Asset Management Inc. ADV Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Neurocrine’s Next VMAT2 Study Adds Depth To Tardive Dyskinesia Story - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Cardinal Health (CAH) - The Globe and Mail
The Bull Case For Neurocrine Biosciences (NBIX) Could Change Following Its Next-Gen VMAT2 Phase 2 Trial - Yahoo Finance
Neurocrine’s New Tardive Dyskinesia Trial And What It Means For Valuation - simplywall.st
Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Savant Capital LLC - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Principal Financial Group Inc. - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by C WorldWide Group Holding A S - MarketBeat
Will Neurocrine Biosciences Inc. stock pay special dividendsJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - Finviz
1.37%
1.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):